X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare, Analyse Cadila Healthcare with ACTAVIS INC. - US - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

CADILA HEALTHCARE vs ACTAVIS (US) - Comparison Results

CADILA HEALTHCARE    Change

Cadila Healthcare is one of the leading players in the Indian pharma market having a presence in both the domestic and international markets. In the international markets, the company had adopted the strategy of competing directly in the generics mar... More

ACTAVIS (US)
   Change

Actavis, Inc. is a global, integrated specialty pharmaceutical company focused on developing, manufacturing and distributing generic, brand and biosimilar products. It develops, manufactures and market generic, branded generic, legacy brands and Over... More

DO YOU LIKE THESE REPORTS? TELL US!

Financials

 CADILA HEALTHCARE   ACTAVIS
EQUITY SHARE DATA
    CADILA HEALTHCARE
Mar-18
ACTAVIS
Dec-14
CADILA HEALTHCARE/
ACTAVIS
5-Yr Chart
Click to enlarge
High Rs55819,612-   
Low Rs36211,962-   
Sales per share (Unadj.) Rs116.33,531.5-  
Earnings per share (Unadj.) Rs17.9-440.7-  
Cash flow per share (Unadj.) Rs23.1324.0-  
Dividends per share (Unadj.) Rs3.500-  
Dividend yield (eoy) %0.80-  
Book value per share (Unadj.) Rs85.47,659.7-  
Shares outstanding (eoy) m1,023.74265.90-   
Bonus/Rights/Conversions ---  
Price / Sales ratio x4.04.5 88.4%   
Avg P/E ratio x25.7-35.8 -71.8%  
P/CF ratio (eoy) x19.948.7 40.8%  
Price / Book Value ratio x5.42.1 261.1%  
Dividend payout %19.60-   
Avg Mkt Cap Rs m470,6644,197,775 11.2%   
No. of employees `00011.821.6 54.7%   
Total wages/salary Rs m18,5450-   
Avg. sales/employee Rs Th10,072.743,473.5 23.2%   
Avg. wages/employee Rs Th1,569.10-   
Avg. net profit/employee Rs Th1,547.7-5,425.0 -28.5%   
INCOME DATA
Net Sales Rs m119,049939,027 12.7%  
Other income Rs m1,132-2,344 -48.3%   
Total revenues Rs m120,181936,684 12.8%   
Gross profit Rs m28,475120,631 23.6%  
Depreciation Rs m5,388203,334 2.6%   
Interest Rs m91129,619 3.1%   
Profit before tax Rs m23,308-114,665 -20.3%   
Minority Interest Rs m6280-   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m0-8,411 0.0%   
Tax Rs m5,644-5,895 -95.7%   
Profit after tax Rs m18,292-117,181 -15.6%  
Gross profit margin %23.912.8 186.2%  
Effective tax rate %24.25.1 471.0%   
Net profit margin %15.4-12.5 -123.1%  
BALANCE SHEET DATA
Current assets Rs m82,005494,747 16.6%   
Current liabilities Rs m60,720360,816 16.8%   
Net working cap to sales %17.914.3 125.4%  
Current ratio x1.41.4 98.5%  
Inventory Days Days7358 126.1%  
Debtors Days Days9866 148.3%  
Net fixed assets Rs m83,703114,665 73.0%   
Share capital Rs m1,0240-   
"Free" reserves Rs m86,4210-   
Net worth Rs m87,4452,036,716 4.3%   
Long term debt Rs m25,5511,067,279 2.4%   
Total assets Rs m180,6533,732,629 4.8%  
Interest coverage x26.6-2.9 -925.9%   
Debt to equity ratio x0.30.5 55.8%  
Sales to assets ratio x0.70.3 261.9%   
Return on assets %10.6-2.3 -453.1%  
Return on equity %20.9-5.8 -363.6%  
Return on capital %22.0-3.0 -730.3%  
Exports to sales %00-   
Imports to sales %00-   
Net fx Rs m31,4410-   
CASH FLOW
From Operations Rs m9,193161,249 5.7%  
From Investments Rs m-9,737-386,092 2.5%  
From Financial Activity Rs m515216,928 0.2%  
Net Cashflow Rs m-29-7,915 0.4%  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster
The reporting currency for ACTAVIS (US) is United States Dollars. All data has been converted at 71.89 Rs / USD

Compare CADILA HEALTHCARE With: MYLAN (US)  ADCOCK INGRAM (S. Africa)  TEVA PHARMA (Israel)  

Compare CADILA HEALTHCARE With: ELDER PHARMA  ALEMBIC LTD  UNICHEM LAB  CIPLA  SANOFI INDIA  



Today's Market

Indian Indices End Week Strong, Pharma Stocks Show Uptick(Pre-Open)

On Friday, share markets in India opened on a positive note and ended the day in green after a volatile day of trading.

Related Views On News

CADILA HEALTHCARE Announces Quarterly Results (2QFY19); Net Profit Down 18.6% (Quarterly Result Update)

Nov 5, 2018 | Updated on Nov 5, 2018

For the quarter ended September 2018, CADILA HEALTHCARE has posted a net profit of Rs 4 bn (down 18.6% YoY). Sales on the other hand came in at Rs 30 bn (down 8.4% YoY). Read on for a complete analysis of CADILA HEALTHCARE's quarterly results.

CADILA HEALTHCARE 2017-18 Annual Report Analysis (Annual Result Update)

Aug 16, 2018 | Updated on Aug 16, 2018

Here's an analysis of the annual report of CADILA HEALTHCARE for 2017-18. It includes a full income statement, balance sheet and cash flow analysis of CADILA HEALTHCARE. Also includes updates on the valuation of CADILA HEALTHCARE.

CADILA HEALTHCARE Announces Quarterly Results (1QFY19); Net Profit Up 274.4% (Quarterly Result Update)

Aug 14, 2018 | Updated on Aug 14, 2018

For the quarter ended June 2018, CADILA HEALTHCARE has posted a net profit of Rs 4 bn (up 274.4% YoY). Sales on the other hand came in at Rs 29 bn (up 29.8% YoY). Read on for a complete analysis of CADILA HEALTHCARE's quarterly results.

Aster DM Healthcare (IPO)

Feb 10, 2018

Should you subscribe to the IPO of Aster DM Healthcare Ltd?

Shalby Ltd. (IPO)

Dec 2, 2017

Should you subscribe to the IPO of Shalby Ltd?

More Views on News

Most Popular

These Are the Kind of Blue Chips You Should Invest In(The 5 Minute Wrapup)

Nov 9, 2018

All blue chip companies are large caps but all large caps are not blue chips.

Get this Small Cap Logistics Company at a 16% Discount Right Now...(Profit Hunter)

Nov 6, 2018

If you turn the clock back, the current macroeconomic climate is nothing new. The markets have seen them all, and every downcycle has been succeeded by gravity defying gains...more so in the small cap space. This time will be no different.

This Was a Large Cap. But Was It Safe?(Chart Of The Day)

Nov 9, 2018

Investing in large caps is not always safe. Consider the right metrics to judge the safety and quality of large caps.

Why the Realty Sector's Recovery Has Been Delayed(Sector Info)

Nov 15, 2018

NBFC and IL&FS crisis have worsened the realty sector woes. Is there a light at the end of the tunnel for real estate sector?

Does it Make Sense to Invest in Offshore Funds?(Outside View)

Nov 6, 2018

Many investors prefer to invest in offshore funds because of the rupee depreciation and on-going downtrend in the markets, but it is to be invested only when there is no option available to invest in India.

More

Small Investments
BIG Returns

Zero To Millions Guide 2019
Get our special report, Zero To Millions
(2019 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

CADILA HEALTHCARE SHARE PRICE


Nov 16, 2018 (Close)

TRACK CADILA HEALTHCARE

  • Track your investment in CADILA HEALTHCARE with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON CADILA HEALTHCARE

CADILA HEALTHCARE 5-YR ANALYSIS

COMPARE CADILA HEALTHCARE WITH

MARKET STATS